Regenxbio (RGNX) Profit After Tax (2014 - 2026)
Regenxbio (RGNX) posted quarterly Profit After Tax of -$67.1 million for Q4 2025, down 41.26% year-over-year from -$114.2 million in Q4 2024, and down 8.32% quarter-over-quarter from -$61.9 million in Q3 2025.
Regenxbio (RGNX) Profit After Tax (2014 - 2026) Analysis & Trends
Regenxbio's Profit After Tax history runs 12 years deep, the most recent figure standing at -$67.1 million for Q4 2025.
- In Q4 2025, Profit After Tax fell 41.26% year-over-year to -$67.1 million; the TTM figure through Dec 2025 stood at -$193.8 million (up 12.21% YoY), while the FY2025 annual figure was -$193.8 million, up 13.24% from the prior year.
- Profit After Tax for Q4 2025 stood at -$67.1 million, down from -$61.9 million in the prior quarter.
- The five-year high for Profit After Tax was $294.0 million in Q4 2021, with the low at -$86.1 million in Q1 2022.
- The 5-year median for Profit After Tax is -$60.6 million (2023), against an average of -$41.5 million.
- Peak annual rise in Profit After Tax reached 735.85% in 2021, while the deepest fall reached 764.37% in 2021.
- Regenxbio's Profit After Tax stood at $294.0 million in 2021, then sank by 115.05% to -$44.2 million in 2022, then sank by 60.18% to -$70.9 million in 2023, then surged by 32.99% to -$47.5 million in 2024, then sank by 41.26% to -$67.1 million in 2025.
- Business Quant data shows RGNX's Profit After Tax at -$67.1 million in Q4 2025, -$61.9 million in Q3 2025, and -$70.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn | 22.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.71 Mn |
| Dec 31, 2025 | -67.10 Mn |
| Sep 30, 2025 | -61.94 Mn |
| Jun 30, 2025 | -70.86 Mn |
| Mar 31, 2025 | 6.08 Mn |
| Dec 31, 2024 | -47.50 Mn |
| Sep 30, 2024 | -57.91 Mn |
| Jun 30, 2024 | -52.03 Mn |
| Mar 31, 2024 | -63.33 Mn |
| Dec 31, 2023 | -70.88 Mn |
| Sep 30, 2023 | -59.18 Mn |
| Jun 30, 2023 | -72.06 Mn |
| Mar 31, 2023 | -62.90 Mn |
| Dec 31, 2022 | -44.25 Mn |
| Sep 30, 2022 | -75.48 Mn |
| Jun 30, 2022 | -70.99 Mn |
| Mar 31, 2022 | -86.10 Mn |
| Dec 31, 2021 | 294.02 Mn |
| Sep 30, 2021 | -58.41 Mn |
| Jun 30, 2021 | -57.53 Mn |